Anand Chaturvedi, MD
Psychiatry · Fairlawn, OHNPI 1700857331
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,741 of the $184,406 with a category attached, or 70.4%. 30 manufacturers reported payments, led by AbbVie at 45.6% of the total. 2025 is the largest year on record at $56,237, more than ten times the $1,375 reported in 2019. Among psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,161 payments — averaging $158.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$84K
- Axsome Therapeutics, Inc.$38K
- Alkermes, Inc.$24K
- Otsuka America Pharmaceutical, Inc.$18K
- Idorsia Pharmaceuticals US Inc$6K
- Neurocrine Biosciences, Inc.$3K
- plus $12K from 24 others
Across 197 payments — averaging $803.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$125K
- Janssen Research & Development, LLC$10K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$9K
- Boehringer Ingelheim International GmbH$6K
- Teva Pharmaceuticals USA, Inc.$5K
- Alkermes, Inc.$3K
What the payments were for
- Consulting fees$27,20015%
- Speaking & faculty fees$129,74170%
- Travel & lodging$7,5284%
- Food & beverage$19,36411%
- Education$5680%
- Gifts$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 308 | $84,077 |
| Axsome Therapeutics, Inc. | 70 | $37,537 |
| Alkermes, Inc. | 100 | $23,701 |
| Otsuka America Pharmaceutical, Inc. | 163 | $17,900 |
| Idorsia Pharmaceuticals US Inc | 22 | $5,722 |
| Neurocrine Biosciences, Inc. | 41 | $3,356 |
| E.r. Squibb & Sons, L.L.C. | 31 | $2,500 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $2,102 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 119 | $1,664 |
| Johnson & Johnson | 32 | $1,445 |
| Teva Pharmaceuticals USA, Inc. | 31 | $1,073 |
| Lundbeck LLC | 83 | $955 |
| Bausch Health US, LLC | 40 | $500 |
| Supernus Pharmaceuticals, Inc. | 24 | $453 |
| Vanda Pharmaceuticals Inc. | 19 | $417 |
| Sunovion Pharmaceuticals Inc. | 27 | $220 |
| Livanova USA, Inc. | 7 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $151 |
| Jazz Pharmaceuticals Inc. | 4 | $137 |
| Avanir Pharmaceuticals, Inc. | 5 | $87 |
| Corium, LLC | 5 | $75 |
| Shire North American Group Inc | 3 | $43 |
| Noven Therapeutics, LLC | 2 | $34 |
| Neuronetics, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Neos Therapeutics, LP | 1 | $11 |
| Validus Pharmaceuticals LLC | 4 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$87,278
- VRAYLAR$80,991
- Auvelity$36,346
- REXULTI$16,173
- QUVIVIQ$5,566
- ABILIFY MYCITE$1,890
- ARISTADA$1,219
- SPRAVATO$796
- QELBREE$251
- COBENFY$245
- INVEGA SUSTENNA$234
- Fanapt$125
- INGREZZA$114
- CAPLYTA$104
- ARISTADA INITIO$103
How this compares
$184,406 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 28 | $245,689 |
| VraylarCariprazine Hcl | 79 | $128,527 |
| Abilify AsimtufiiAripiprazole | 21 | $107,721 |
| RexultiBrexpiprazole | 56 | $82,067 |
| CaplytaLumateperone Tosylate | 23 | $43,751 |
| Abilify MaintenaAripiprazole | 16 | $43,064 |
| TrintellixVortioxetine Hydrobromide | 50 | $38,865 |
| AuvelityDextromethorphan Hbr/Bupropion | 28 | $29,364 |
| Lurasidone Hcl | 36 | $17,610 |
| BelsomraSuvorexant | 35 | $11,545 |
| Aripiprazole | 136 | $11,311 |
| Bupropion XlBupropion Hcl | 361 | $7,843 |
| QuviviqDaridorexant Hcl | 14 | $6,849 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 273 | $6,074 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 88 | $5,989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $3,356 | $245,68928 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti, Abilify Maintena | $17,900 | $232,85293 claims |
| AbbVieVraylar | $84,077 | $128,52779 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,664 | $43,75123 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $151 | $38,86550 claims |
| Axsome Therapeutics, Inc.Auvelity | $37,537 | $29,36428 claims |
| MerckBelsomra | $16 | $11,54535 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $5,722 | $6,84914 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $3,007137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Fairlawn
- Anil ParikhFairlawn$293K
- Henry NasrallahCincinnati$3.8M
- Fred RomeoColumbus$2.3M
- Amita PatelDayton$2.1M
- Pradeep ManudhaneCanton$1.5M
- Michael SaribalasColumbus$1.2M
- Kevin WareColumbus$1.1M
- Binit ShahCleveland$913K
- Paul KeckCincinnati$739K
- Ali MelhemSteubenville$681K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.